Burkina FasoTuberculosis profile
Population  2016 19 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.6 (0.97–2.4) 8.7 (5.2–13)
Mortality (HIV+TB only) 0.31 (0.19–0.44) 1.6 (1–2.4)
Incidence  (includes HIV+TB) 9.4 (6.1–13) 51 (33–72)
Incidence (HIV+TB only) 0.87 (0.55–1.3) 4.7 (3–6.7)
Incidence (MDR/RR-TB)** 0.3 (0.18–0.41) 1.6 (0.97–2.2)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.46 (0.28–0.64) 2.9 (1.8–4.1) 3.4 (2.1–4.7)
Males 0.52 (0.32–0.73) 5.5 (3.4–7.7) 6.1 (3.7–8.4)
Total 0.99 (0.6–1.4) 8.5 (5.1–12) 9.4 (6.1–13)
TB case notifications, 2016  
Total cases notified 5 918
Total new and relapse 5 677
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status 90%
          - % pulmonary 83%
          - % bacteriologically confirmed among pulmonary 81%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 60% (42–93)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.21 (0.11–0.34)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 492 10%
          - on antiretroviral therapy 403 82%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  170
(120–220)
Estimated % of TB cases with MDR/RR-TB 2.1% (1.2–3) 14% (8.5–20)  
% notified tested for rifampicin resistance <1% 58% 376
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 58, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 41, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 78% 5 553
Previously treated cases, excluding relapse, registered in 2015 72% 272
HIV-positive TB cases registered in 2015 70% 515
MDR/RR-TB cases started on second-line treatment in 2014 68% 34
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
23% (21–25)
TB financing, 2017  
National TB budget (US$ millions) 8.8
Funding source: 2% domestic, 23% international, 75% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data